These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 25820067)
1. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. Jin X; Morgan C; Yu X; DeRosa S; Tomaras GD; Montefiori DC; Kublin J; Corey L; Keefer MC; Vaccine; 2015 May; 33(20):2347-53. PubMed ID: 25820067 [TBL] [Abstract][Full Text] [Related]
2. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial. Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679 [TBL] [Abstract][Full Text] [Related]
3. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ; J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336 [TBL] [Abstract][Full Text] [Related]
4. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. Lhomme E; Richert L; Moodie Z; Pasin C; Kalams SA; Morgan C; Self S; De Rosa SC; Thiébaut R PLoS One; 2016; 11(4):e0152952. PubMed ID: 27124598 [TBL] [Abstract][Full Text] [Related]
5. Improvement in T helper 1-related immune responses in BALB/c mice immunized with an HIV-1 gag plasmid combined with a chimeric plasmid encoding interleukin-18 and flagellin. Chen YL; Chen YS; Hung YC; Liu PJ; Tasi HY; Ni WF; Hseuh PT; Lin HH Microbiol Immunol; 2015 Aug; 59(8):483-94. PubMed ID: 26094825 [TBL] [Abstract][Full Text] [Related]
6. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Catanzaro AT; Roederer M; Koup RA; Bailer RT; Enama ME; Nason MC; Martin JE; Rucker S; Andrews CA; Gomez PL; Mascola JR; Nabel GJ; Graham BS; Vaccine; 2007 May; 25(20):4085-92. PubMed ID: 17391815 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741 [TBL] [Abstract][Full Text] [Related]
8. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. Barouch DH; Santra S; Tenner-Racz K; Racz P; Kuroda MJ; Schmitz JE; Jackson SS; Lifton MA; Freed DC; Perry HC; Davies ME; Shiver JW; Letvin NL J Immunol; 2002 Jan; 168(2):562-8. PubMed ID: 11777947 [TBL] [Abstract][Full Text] [Related]
9. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. Stone GW; Barzee S; Snarsky V; Kee K; Spina CA; Yu XF; Kornbluth RS J Virol; 2006 Feb; 80(4):1762-72. PubMed ID: 16439533 [TBL] [Abstract][Full Text] [Related]
10. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. Kalams SA; Parker SD; Elizaga M; Metch B; Edupuganti S; Hural J; De Rosa S; Carter DK; Rybczyk K; Frank I; Fuchs J; Koblin B; Kim DH; Joseph P; Keefer MC; Baden LR; Eldridge J; Boyer J; Sherwat A; Cardinali M; Allen M; Pensiero M; Butler C; Khan AS; Yan J; Sardesai NY; Kublin JG; Weiner DB; J Infect Dis; 2013 Sep; 208(5):818-29. PubMed ID: 23840043 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. Kalams SA; Parker S; Jin X; Elizaga M; Metch B; Wang M; Hural J; Lubeck M; Eldridge J; Cardinali M; Blattner WA; Sobieszczyk M; Suriyanon V; Kalichman A; Weiner DB; Baden LR; PLoS One; 2012; 7(1):e29231. PubMed ID: 22242162 [TBL] [Abstract][Full Text] [Related]
12. Co-administration of plasmid-encoded granulocyte-macrophage colony-stimulating factor increases human immunodeficiency virus-1 DNA vaccine-induced polyfunctional CD4+ T-cell responses. Santana VC; Almeida RR; Ribeiro SP; Ferreira LC; Kalil J; Rosa DS; Cunha-Neto E Mem Inst Oswaldo Cruz; 2015 Dec; 110(8):1010-6. PubMed ID: 26602876 [TBL] [Abstract][Full Text] [Related]
13. Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine. Rosa DS; Ribeiro SP; Fonseca SG; Almeida RR; Santana VC; Apostólico Jde S; Kalil J; Cunha-Neto E AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1077-88. PubMed ID: 26149745 [TBL] [Abstract][Full Text] [Related]
14. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha. Jiang W; Ren L; Jin N J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910 [TBL] [Abstract][Full Text] [Related]
15. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757 [TBL] [Abstract][Full Text] [Related]
16. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. Jacobson JM; Zheng L; Wilson CC; Tebas P; Matining RM; Egan MA; Eldridge J; Landay AL; Clifford DB; Luetkemeyer AF; Tiu J; Martinez AL; Janik J; Spitz TA; Hural J; McElrath J; Frahm N; J Acquir Immune Defic Syndr; 2016 Feb; 71(2):163-71. PubMed ID: 26761518 [TBL] [Abstract][Full Text] [Related]
17. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963 [TBL] [Abstract][Full Text] [Related]
18. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults. Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526 [TBL] [Abstract][Full Text] [Related]
19. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387 [TBL] [Abstract][Full Text] [Related]
20. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine. Cheeseman HM; Day S; McFarlane LR; Fleck S; Miller A; Cole T; Sousa-Santos N; Cope A; Cizmeci D; Tolazzi M; Hwekwete E; Hannaman D; Kratochvil S; McKay PF; Chung AW; Kent SJ; Cook A; Scarlatti G; Abraham S; Combadiere B; McCormack S; Lewis DJ; Shattock RJ Hum Gene Ther; 2018 Sep; 29(9):1011-1028. PubMed ID: 30027768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]